BioArctic, with a current market capitalization of $158.45 million, reported a robust performance for the fourth quarter of 2024, achieving net revenues of $101 million, with a significant increase in ...
More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback